Krystal sells the first gene therapy for a severe skin-blistering disease.
Krystal Biotech, Inc. (KRYS) is expected to report earnings on Monday, November 2, 2026, after the close. Estimated release time 07:30 ET. Consensus EPS estimate is $1.91.
| Report date | Quarter | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|---|
| 2026-08-03 | FY2026 Q2 | $1.70 | $1.85 | +8.8% | $119.22M |
| 2026-05-04 | FY2026 Q1 | $1.45 | $1.91 | +31.7% | $116.36M |
| 2026-02-17 | FY2025 Q4 | $1.62 | $1.77 | +9.3% | $107.11M |
| 2025-11-03 | FY2025 Q3 | $1.12 | $2.74 | +144.6% | $97.80M |
| 2025-08-04 | FY2025 Q2 | $1.08 | $1.33 | +23.1% | $96.04M |
| 2025-05-06 | FY2025 Q1 | $1.38 | $1.24 | -10.1% | $88.18M |
| 2025-02-19 | FY2024 Q4 | $1.29 | $1.58 | +22.5% | $91.14M |
| 2024-11-04 | FY2024 Q3 | $0.90 | $0.95 | +5.6% | $83.84M |
KRYS has beaten consensus EPS in 7 of its last 8 reported quarters.
Highlights from KRYS's Aug 3 report: EPS of $1.85 — a beat vs the $1.70 estimate (+9%); revenue of $119M — in line with the $121M consensus. Focus now shifts to Vyjuvek growth and pipeline.
See KRYS on the live calendar →